Stockscreener 앱 받기
6.00
3.77%
-0.37
시간 외 거래:
6.03
0.03
+0.50%
전일 마감가:
$6.37
열려 있는:
$6.55
하루 거래량:
102.81K
Relative Volume:
0.05
시가총액:
$27.46M
수익:
-
순이익/손실:
$-54.66M
주가수익비율:
-0.3146
EPS:
-19.0729
순현금흐름:
$-49.98M
1주 성능:
-24.04%
1개월 성능:
-25.33%
6개월 성능:
-48.75%
1년 성능:
+8.21%
1일 변동 폭
$5.765
$6.63
1주일 범위
$5.765
$8.17
52주 변동 폭
$1.55
$15.74
Nextcure Inc Stock (NXTC) Company Profile
명칭
Nextcure Inc
전화
240-399-4900
주소
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
6.00 | 32.04M | 0 | -54.66M | -49.98M | -19.07 |
VRTX
Vertex Pharmaceuticals Inc
|
513.35 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
774.83 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
985.16 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.65 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
195.92 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-03-05 | 업그레이드 | Truist | Hold → Buy |
| 2021-01-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-07-16 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-07-13 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-13 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-06-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-05-26 | 개시 | JMP Securities | Mkt Outperform |
| 2020-03-24 | 개시 | The Benchmark Company | Buy |
| 2020-03-02 | 개시 | ROTH Capital | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-05 | 개시 | Needham | Buy |
| 2019-11-26 | 개시 | BTIG Research | Buy |
| 2019-07-09 | 개시 | BofA/Merrill | Buy |
| 2019-06-03 | 개시 | Morgan Stanley | Overweight |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Nextcure Inc 주식(NXTC)의 최신 뉴스
NextCure Inc (NASDAQ: NXTC) Stock Price, News & Analysis - Kalkine
Nextcure Stock Price Forecast. Should You Buy NXTC? - StockInvest.us
NXTC|NextCure Inc|Price:7.860|Chg%:+0.040 - TradingKey
NextCure Ends Beltsville Lease to Cut Operating Costs - TipRanks
About 30,000 sq ft of lab as NextCure (NXTC) exits Maryland site—what it paid to leave early - Stock Titan
NextCure Enters Into Ninth Amendment To Lease Agreement And Vacates Premises At 8000 Virginia Manor Road - marketscreener.com
NextCure - thepharmaletter.com
NextCure (NXTC) Q2 2026 Earnings: Profit Per Share Falls Below Its Benchmark for the Current Session - vinanet.vn
NextCure (NASDAQ: NXTC) plans Avere merger backed by $820M raise - Stock Titan
NextCure (NXTC) Share-Price Review: Declines 11.15% to $6.85 at the Close; Current Range Read: the Near-Term Reference Band Stretches From $6.51 to $7.19 under the Current SnapshotExtension Target - vinanet.vn
Ikarian Capital discloses 9.99% NextCure (NXTC) stake including large warrant position - Stock Titan
NextCure (NXTC) gains 15.8% beneficial owner in ADAR1 Capital and manager - Stock Titan
NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake - Stock Titan
Affinity Asset Advisors discloses 6.4% NextCure (NXTC) stake via stock and warrants - Stock Titan
NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Major Former Stakeholder Makes a Significant Move in NextCure Stock - TipRanks
Simcere Zaiming sells $184,800 of NextCure stock By Investing.com - Investing.com India
Adage Capital files Schedule 13G showing 7.67% NextCure (NXTC) ownership - Stock Titan
Simcere Zaiming sells $184,800 of NextCure stock - Investing.com
Simcere group (NXTC) trims NextCure stake, ends 10% beneficial ownership - Stock Titan
RTW Biotech's Avere to go public in US in reverse merger with NextCure - London South East
RTW Biotech Opportunities (RTWG) Supports Avere Therapeutics’ $820M Capital Raise and NextCure Reverse Merger - Kalkine Media
NextCure (NXTC) plans reverse merger with Avere and $820M financings - Stock Titan
Xcellon Acquires 40,000 Sq ft Maryland Facility from NextCure to Deliver a cGMP-Ready CRDMO for ADCs - BioBuzz
Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics - The Manila Times
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - Nasdaq
XCELLON BIOLOGICS: CO ACQUIRES GMP MANUFACTURING FACILITY FROM NEXTCURE - Moomoo
NextCure Inc (NXTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results - The Manila Times
NextCure reports Q2 2026 net loss $14.9M, cash $20.1M as it pursues merger with Avere - TradingView
NextCure, Inc. Q2 2026: Net income $(14.9)M, EPS $(2.80) — 10-Q Summary - TradingView
NextCure (NASDAQ: NXTC) details Avere merger, $320M financing and going concern risk - Stock Titan
NextCure (Nasdaq: NXTC) details Q2 2026 loss and Avere merger - Stock Titan
NextCure (NXTC) details two-step Avere merger plan and upcoming Form S-4 - Stock Titan
Form 4 NextCure Inc For: 4 August By Investing.com - Investing.com UK
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares By Investing.com - Investing.com India
ADAR1 Capital Management reports NextCure common share purchase worth $3.59 million - Bitget
ADAR1-managed funds buy 329,153 shares of NextCure (NXTC) - Stock Titan
Avere Therapeutics - thepharmaletter.com
NextCure Inc expected to post a loss of $1.93 a shareEarnings Preview - TradingView
NextCure Stock Short Interest Rises to 32.54% | NXTC Stock News - Quiver Quantitative
NextCure, Inc. Revenue Breakdown – NASDAQ:NXTC - TradingView
NextCure (NXTC) Holds Steady Near Key Support LevelsMarket Cap Weight - vinanet.vn
Form 4 NextCure Inc For: 29 July By Investing.com - Investing.com South Africa
Adar1 capital management increases NextCure (NXTC) stake by $87,712 - Investing.com Canada
NextCure Inc. (NXTC) Surges 5.86% as Biotech Stock Approaches Key Resistance LevelTriple MA Cross - dars.gov.et
Nextcure Inc (NXTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
2.40%
자본화:
|
볼륨(24시간):